About Innocoll

Innocoll is a biotherapeutics pharmaceutical company committed to improving the status quo and finding answers to unmet needs

XARACOLL®

Our lead investigational product is a drug-device surgical implant being developed for potential uses in addressing postsurgical pain

Latest News

Innocoll Biotherapeutics plc Announces First Patients In Phase 3 Clinical Trials for Label Expansion of Xaracoll® (bupivacaine hydrochloride) Implant

Results of implant’s safety, efficacy and pharmacokinetics for use in various open soft-tissue surgeries expected in first quarter 2022 April...
Read More

Louis Pascarella Appointed Chief Executive Officer of Innocoll

Louis Pascarella has been named the company’s Chief Executive Officer and a member of Innocoll’s Board of Directors. Pascarella, who will retain his current role of President, succeeds Rich Fante, who is stepping down after a successful tenure as CEO and has agreed to serve as an adviser to Innocoll’s Board for at least the next year to ensure a smooth transition.
Read More

Innocoll Holdings Limited Appoints Richard Fante as Chief Executive Officer

ATHLONE, Ireland & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Innocoll Holdings Limited (“Innocoll”), a specialty pharmaceutical company wholly owned by Gurnet Point Capital, announced...
Read More